opt-80 and Diarrhea

opt-80 has been researched along with Diarrhea* in 1 studies

Reviews

1 review(s) available for opt-80 and Diarrhea

Article	Year
Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:2 Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway. Topics: Animals; Anti-Bacterial Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clostridioides difficile; Diarrhea; Drug Evaluation, Preclinical; Enterocolitis, Pseudomembranous; Glycosides; Humans	2007

Article

Year

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:2

Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.

Topics: Animals; Anti-Bacterial Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clostridioides difficile; Diarrhea; Drug Evaluation, Preclinical; Enterocolitis, Pseudomembranous; Glycosides; Humans

2007